UBS Group
UBX

UBS Group’s Unity Biotechnology UBX Stock Holding History

UBS Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-152,327
Closed -$58.5K – 10950
2025
Q2 		$58.5K Buy
152,327
+128,026
+527% +$110K ﹤0.01% 7648
2025
Q1 		$25.3K Buy
24,301
+16,066
+195% +$29K ﹤0.01% 8063
2024
Q4 		$8.04K Buy
8,235
+7,848
+2,028% +$9.75K ﹤0.01% 8429
2024
Q3 		$569 Buy
+387
New +$568 ﹤0.01% 8890
2024
Q2 		– Sell
-3,494
Closed -$5.73K – 10109
2024
Q1 		$5.73K Sell
3,494
-5,806
-62% -$10.1K ﹤0.01% 7511
2023
Q4 		$17.9K Buy
9,300
+8,940
+2,483% +$16.6K ﹤0.01% 7170
2023
Q3 		$864 Buy
360
+350
+3,500% +$927 ﹤0.01% 8241
2023
Q2 		$26 Buy
+10
New +$26 ﹤0.01% 8667
2023
Q1 		– Sell
-8,004
Closed -$21.9K – 10394
2022
Q4 		$21.9K Buy
8,004
+7,321
+1,072% +$21.3K ﹤0.01% 7560
2022
Q3 		$3K Sell
683
-375
-35% -$2.37K ﹤0.01% 9589
2022
Q2 		$6K Buy
1,058
+58
+6% +$484 ﹤0.01% 8724
2022
Q1 		$11K Buy
1,000
+605
+153% +$6.79K ﹤0.01% 8323
2021
Q4 		$6K Sell
395
-298
-43% -$6.51K ﹤0.01% 9301
2021
Q3 		$22K Buy
693
+568
+454% +$20K ﹤0.01% 7071
2021
Q2 		$6K Sell
125
-288
-70% -$13.9K ﹤0.01% 8470
2021
Q1 		$25K Buy
413
+190
+85% +$13K ﹤0.01% 7180
2020
Q4 		$12K Sell
223
-324
-59% -$15.6K ﹤0.01% 7358
2020
Q3 		$19K Buy
547
+52
+11% +$3.29K ﹤0.01% 6355
2020
Q2 		$43K Sell
495
-801
-62% -$59.4K ﹤0.01% 5990
2020
Q1 		$75K Sell
1,296
-1,910
-60% -$120K ﹤0.01% 5520
2019
Q4 		$231K Buy
3,206
+969
+43% +$68.4K ﹤0.01% 5507
2019
Q3 		$136K Sell
2,237
-1,233
-36% -$87.2K ﹤0.01% 5559
2019
Q2 		$329K Sell
3,470
-170
-5% -$14.5K ﹤0.01% 4584
2019
Q1 		$295K Buy
3,640
+201
+6% +$22.8K ﹤0.01% 4379
2018
Q4 		$559K Sell
3,439
-151
-4% -$20K ﹤0.01% 4175
2018
Q3 		$585K Buy
3,590
+2,779
+343% +$458K ﹤0.01% 4307
2018
Q2 		$122K Buy
+811
New +$119K ﹤0.01% 5299

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

UBS Group's UBX Position: Q3 2025 in Review

UBS Group sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 152,327 shares — an estimated $58.5K sold.

UBS Group first reported a position in UBX in Q2 2018 and held it in 27 quarters. The position peaked at $585K in Q3 2018. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • UBS Group reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 152,327 Unity Biotechnology shares in Q3 2025, an estimated $58.5K.
  • UBS Group first reported a position in Unity Biotechnology in Q2 2018 and held it in 27 quarters.
  • UBS Group's Unity Biotechnology position peaked at $585K in Q3 2018.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.